About InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar)
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Relatlimab making it ideal for research use. This Relatlimab biosimilar reacts with human LAG-3 also known as CD223. LAG-3 is a 70 kDa type I transmembrane glycoprotein encoded by the Lag3 gene that belongs to the immunoglobulin superfamily. LAG-3 is expressed by activated T lymphocytes, NK cells, and T regulatory cells. LAG-3’s main ligand is MHC class II which it binds to with a higher affinity than even CD4 does. Upon binding LAG-3 is thought to play similar roles as CTLA-4 and PD-1 including downregulation of TCR signaling and inhibition of CD4-dependent T cell function. LAG-3 has also been demonstrated to contribute to the suppressor function of T regulatory cells. In contrast to inhibition, LAG-3 has been shown to promotes immune responses by activating antigen-presenting cells. Relatlimab is a LAG-3 inhibitor. A combination of Relatlimab with the immunomodulatory drug lenalidomide significantly increases IL-2 production by T cells and antibody-dependent cytotoxicity mediated by NK cells.
InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar) Specifications
| Isotype | Human IgG4, κ |
| Recommended Isotype Control(s) | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human LAG-3 |
| Reported Applications | ELISA |
| Formulation | PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin | <0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay |
| Aggregation | <5% Determined by SEC |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein G |
| RRID | AB_2927531 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |